SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Hagens Berman works with Veru Inc. (Nasdaq: VERU) Investors who have suffered significant losses should report their losses now.
Class period: May 11, 2022 to November 9, 2022
Leading Plaintiff Deadlines: February 6, 2023
visit: www.hbsslaw.com/investor-fraud/VERU
Contact a Lawyer Now: VERU@hbsslaw.com
844-916-0895
Veru Inc. (NASDAQ: VERU) Securities Fraud Class Action:
The complaint alleges that, throughout the class, defendants allege Phase 3 trial data and communications between the Company and the FDA regarding subvisabrine (VERU-111), an orally administered COVID 19 drug intended for the treatment of hospitalized patients. They allege that they have misrepresented and concealed material adverse facts. High risk of acute respiratory distress syndrome.
Specifically, Veru told investors that the data from the Phase 3 trial was sufficient to support an Emergency Use Authorization (“EUA”) and a New Drug Application (“NDA”) without further research. ) even led me to believe it could support the submission of VERU’s filings therefore masked the real risks the company faces in obtaining approval for his EUA application.
On November 9, 2022, investors learned the truth when Veru announced that its FDA Advisory Committee (“AdCom”) had voted against approval of Saviavrin under the agency’s EUA pathway. Separately, AdCom’s briefing document highlights “several uncertainties in the data that may affect the clinical interpretation of efficacy results.”
The news sent Veru’s stock price down 53% in a single day.
“We are focused on investor losses and demonstrate that Veru misled investors about the sufficiency of the data they submitted to support the Saviavrin EUA and their communication with the FDA,” it said. said Reed Kathrein, partner at Hagens Berman, who led the study.
If you have invested in Veru and lost a lot of money, or if you have knowledge that could help you investigate the company, please click here to discuss your legal rights with Hagens Berman.
Whistleblower: Anyone with nonpublic information about Veru should consider cooperating with the investigation or using the SEC Whistleblower Program. Under the new program, whistleblowers who provide original information can be rewarded up to 30% on total successful recoveries by the SEC. Please call Reed Kathrein for more information. 844-916-0895 Or send an email to VERU@hbsslaw.com.
About Hagens Bermann
Hagens Berman is a national law firm with over 80 attorneys in eight offices in eight cities nationwide. The firm represents investors, whistleblowers, workers and consumers in complex litigation. For more information on the company and its success, please visit hbsslaw.com.Visit us for the latest news newsroom Or follow us on Twitter. @classactionlaw.
contact:
Reed Kathline, 844-916-0895
